PRISM MarketView Features Q&A with Dr. Ellen Kim: Soligenix's HyBryte™— Lighting the Way Towards Commercial Success with Promising FLASH Study Results

Future Directions: Looking ahead, Dr. Kim highlighted upcoming milestones, saying, "In the short term, we expect to issue results from the IIS as data warrants... Additionally, these initial results are very exciting and build upon the increasing body of positive HyBryte™ data as we move into the 18-week confirmatory FLASH2 study later this year." PRISM MarketView does not provide investment advice. M PRISM M MarketView Highlights from the Q&A: About Soligenix recommendation of any security. PCG may be comp ...